NCT03556228: Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma

NCT03556228
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Only TNBC patients & patients with tumors that have an NTRK mutation, fusion, overexpression, translocation, amplification or other alterations are eligible for the expansion phase (Part 2)
Exclusions: 
https://ClinicalTrials.gov/show/NCT03556228

Comments are closed.

Up ↑